1. Home
  2. Press release
Oct 01, 2019 11:46 JST

Source: Eisai

Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

TOKYO, Oct 01, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE- 146/Study 111 evaluating LENVIMA, an orally available kinase inhibitor discovered by Eisai , plus KEYTRUDA, Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy. The findings were presented in a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract #994O).

For the full report, visit https://www.eisai.com/news/2019/pdf/enews201977pdf.pdf.

Contact:
Eisai Co., Ltd. 
Media Relations 
+81-(0)3-3817-5120

Merck & Co., Inc., Kenilworth, N.J., U.S.A. 
Media Relations 
Pamela Eisele: (267) 305-3558 
Kristen Drake: (908) 334-4688
Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
 
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
 
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
 
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
 
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
 
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
 
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
 
LEQEMBI(R) (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Australia
September 24 2025 18:04 JST
 
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
September 17 2025 17:20 JST
 
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month
September 12 2025 12:20 JST
 
More Press release >>

Latest Press Release


NEC and Siemens collaborate to accelerate smart factory innovation
Nov 05, 2025 00:57 JST

Exhibiting at the Space Tech Expo Europe 2025 in Bremen, Germany
Nov 05, 2025 00:49 JST

Honda Announces Electric Motorcycle Business Brand Promise and Four Core Values
Nov 05, 2025 00:35 JST

Honda Unveils Its First Electric Motorcycle, the Honda WN7, at EICMA 2025
Nov 05, 2025 00:20 JST

Honda Unveils V3R 900 E-Compressor Prototype Equipped with V3 Engine with Electronically-controlled Compressor at EICMA 2025
Nov 05, 2025 00:00 JST

Honda Presents World Premiere of CB1000GT Sport Tourer at EICMA 2025
Nov 04, 2025 23:55 JST

New CB1000GT, global debut of Honda WN7 electric motorcycle, expansion of Honda E-Clutch line-up and V3R 900 E-Compressor Prototype lead Honda's EICMA 2025 line-up
Nov 04, 2025 23:40 JST

Honda Motorcycle Business Product Marks and New Emblem
Nov 04, 2025 23:21 JST

FWD Group reports strong new business growth
Nov 03, 2025 10:03 JST

Hitachi High-Tech Announces the SU9600: Next-Generation Ultrahigh-Resolution Scanning Electron Microscope with High Throughput
Nov 01, 2025 00:45 JST

Sharp to Introduce AQUOS sense10 Smartphone
Nov 01, 2025 00:27 JST

Fujitsu to provide digital ticketing service for NTT DOCOMO's new d ticket platform
Nov 01, 2025 00:07 JST

HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
Oct 31, 2025 09:30 JST

MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO's "Development of Technologies for Building a Competitive Hydrogen Supply Chain" Project
Oct 30, 2025 23:14 JST

NEC and e& Sign MoU to Drive Joint Sustainability Initiatives
Oct 30, 2025 22:46 JST

MHI Thermal Systems Launches Two New Models of Air-to-Water Heat Pumps Using Natural Refrigerant R290 for European Market
Oct 30, 2025 22:19 JST

Hitachi Energy and Blackstone Energy Transition Partners enter strategic partnership to create leading energy service provider in North America
Oct 30, 2025 21:40 JST

MHI-MS to Conduct Demonstration Testing of Vehicle Transport Robots at Nakagusuku Port in Okinawa
Oct 30, 2025 17:58 JST

DENSO Hosted a Press Briefing at JAPAN MOBILITY SHOW 2025
Oct 30, 2025 17:29 JST

Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 30, 2025 14:43 JST
 More Latest Release >>